104 / 1068
The Royal Marsden
When is it important to know?
•
Patients undergoing major radical surgery with curative intent: e.g.
ELAPE/ extenteration
•
Oligometastatic disease – potentially resectable vs widespread
metastatic disease
•
Synchronous metastatic disease control – liver first/ primary first?
•
Type and duration of adjuvant chemotherapy
•
Biomarker for resistance to 1
st
line chemotherapy
•
Unexplained rise in CEA level